Who is sponsoring NCT05375396?

NCT05375396 is sponsored by John Hale.

What drugs are being tested in NCT05375396?

Interventions in NCT05375396: Streptococcus salivarius M18 lozenges, Streptococcus salivarius M18 dairy free lozenges.

What condition does NCT05375396 study?

NCT05375396 studies Microbial Colonization.

Is NCT05375396 still recruiting?

NCT05375396 is currently status unknown. Last updated 16 May 2022.

Last reviewed 2022-05-16 · How we verify

NCT05375396

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Microbial Colonization of Dairy Free Oral Probiotics

Status unknown NA Last updated 16 May 2022

What this trial tests

NA trial testing Streptococcus salivarius M18 lozenges in Microbial Colonization in 30 participants. Status unknown.

Timeline

1 June 2022

Primary endpoint
1 July 2022

1 August 2022

Quick facts

Lead sponsor	John Hale
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	basic science
Enrollment	30
Start date	1 June 2022
Primary completion	1 July 2022
Estimated completion	1 August 2022
Sites	1 location across New Zealand

Drugs / interventions tested

Streptococcus salivarius M18 lozenges
Streptococcus salivarius M18 dairy free lozenges

Conditions studied

Microbial Colonization — all drugs for Microbial Colonization →

Sponsor

John Hale

Who can join

Adults 18 to 80, any sex, with Microbial Colonization. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to evaluate the colonization efficacy of probiotic lozenges containing dairy and dairy free probiotic Streptococcus salivarius M18, in healthy adults

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Microbial Colonization

Currently open trials in the same condition.

NCT06970262 — FMT for Lung and Associated-organ Rescue Efficacy in ARDS Patients · NA · recruiting
NCT06805994 — Administering NMT to Reestablish Infant Nasal Microbiome Diversity Following Intranasal Mupirocin Treatment · Phase 1 · recruiting
NCT06938386 — Pilot Haskap Metabolite Timing Project · NA · active not recruiting
NCT06920641 — Effects of Tagatose on Glycemic Response and Gastrointestinal Microbiota in Healthy Adults · NA · recruiting
NCT06541808 — Balance, Autonomic Response, and Sensory Modulation to Dosage of Mechanical Vagal Stimulation in Healthy Adults · NA · recruiting

Other John Hale trials

Trials by the same sponsor.

NCT07384130 — Oral Probiotics for Halitosis in Healthy Adults · NA · not yet recruiting
NCT05374070 — Antiviral Activity of Oral Probiotics · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05375396 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by John Hale
Last refreshed: 16 May 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05375396.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing